Trial Profile
Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 11 Dec 2017 Status changed from active, no longer recruiting to completed.
- 09 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
- 08 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Nov 2016 as per ClinicalTrials.gov record.